Potential role of immunotherapy in advanced non-small-cell lung cancer

De Mello, Ramon Andrade; Veloso, Ana Flavia; Catarina, Paulo Esrom; Nadine, Sara; Antoniou, Georgios

http://hdl.handle.net/10400.1/12006

Utilize este identificador para referenciar este registo.

Nome:	Descrição:	Tamanho:	Formato:
12006.pdf		1.28 MB	Adobe PDF	Ver/Abrir

Contacte-nos

Autores

De Mello, Ramon Andrade

Veloso, Ana Flavia

Catarina, Paulo Esrom

Nadine, Sara

Antoniou, Georgios

Resumo(s)

Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib, erlotinib, and afatinib) or with anaplastic lymphoma kinase inhibitors (eg, crizotinib and ceritinib). As a result, anti-PD- 1/PD-L1 and CTLA-4 inhibitors may play a novel role in the improvement of outcomes in a metastatic setting. The regulation of immune surveillance, immunoediting, and immunoescape mechanisms may play an interesting role in this regard either alone or in combination with current drugs. Here, we discuss advances in immunotherapy for the treatment of metastatic non-small-cell lung cancer as well as future perspectives within this framework.

Palavras-chave

Immune checkpoint inhibitors Predictive biomarker Tumor escape Ifn-gamma Nivolumab Immunosurveillance Anti-Pd-1 Nsclc Suppression Management

URI

http://hdl.handle.net/10400.1/12006

Editora

Dove Medical Press

DOI

10.2147/OTT.S90459

Coleções

FCB2-Artigos (em revistas ou actas indexadas)

Métricas Alternativas

Ver registo completo